ACADIA Pharmaceuticals (ACAD): EVP, CHIEF FINANCIAL OFFICER Schneyer Mark C. sold $69,342 worth of shares (3,321 units at $20.88) (SEC Form 4)
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for ACAD
Across the 27 sessions after earlier ACAD headlines, the stock closed higher 12 times and lower 15 times, with a median move of 2.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ACAD | SPY |
|---|---|---|---|
| Oct 29, 2026 | Acadia Pharmaceuticals to Participate in the UBS Global Biopharma Conference 2026 | +2.2% | -0.4% |
| Oct 22, 2026 | Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026 | +0.6% | -1.2% |
| Oct 19, 2026 | FDA Approval for DAYBUE STIX issued to ACADIA PHARMS INC | +3.6% | +0.4% |
| Oct 13, 2026 | ACADIA Pharmaceuticals downgraded by UBS with a new price target | -4.1% | -0.0% |
| Sep 29, 2026 | Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041 | -1.5% | -0.2% |
| Sep 24, 2026 | Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP) | -12.8% | -0.1% |
Earlier insider filings at ACAD
- Aug 7, 2026EVP, CHIEF FINANCIAL OFFICER Schneyer Mark C. exercised 20,141 shares at a strike of $17.84 and sold $587,242 worth of shares (20,141 units at $29.16) as part of a pre-agreed trading plan (SEC Form 4)
- Jul 31, 2026EVP, Head of Research & Dev Thompson Elizabeth H.Z. converted options into 32,272 shares and sold $432,663 worth of shares (16,558 units at $26.13) as part of a pre-agreed trading plan, increasing direct ownership by 479% to 18,994 units (SEC Form 4) (tax withholding)
- Jun 29, 2026PRINCIPAL ACCOUNTING OFFICER Kihara James sold $297,912 worth of shares (11,421 units at $26.08) as part of a pre-agreed trading plan, decreasing direct ownership by 47% to 13,088 units (SEC Form 4)
- Jun 2, 2026Director Baker Bros. Advisors Lp was granted 37,244 shares (SEC Form 4)
- Jun 1, 2026Director Harrigan Edmund converted options into 8,107 shares, increasing direct ownership by 23% to 43,148 units (SEC Form 4)
Quantisnow market dataNASDAQ
ACAD
ACADIA Pharmaceuticals Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 1985
Get push alerts for ACAD
Full ACAD profile on Quantisnow Follow ACAD and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time